Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | Guidance and guidelines

Documents

A list of downloadable documents created during development.

Background information

TA106 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information
TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive 20 December 2013 111.64 KB
TA106 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information
TA106 Hepatitis C - peginterferon alfa and ribavirin: - Appendix A - provisional matrix of stakeholders 14 October 2013 100.31 KB
TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013 14 October 2013 534.1 KB
Review decision, August 2008 information
Review decision - March 2008: table of comments 13 August 2008 135.33 KB
Review proposal, March 2008 information
Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments information
Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments 23 August 2006 42.03 KB

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination

Response to consultee and commentator comments on the ACD

Response to consultee and commentator comments on the ACD 12 May 2006 89.68 KB

Consultee and commentator comments on the ACD

Consultee and commentator comments on the ACD
Association of Nurses in Substance Abuse 12 May 2006 26.33 KB
British Society of Gastroenterology 12 May 2006 18.98 KB
Department of Health Development Agency 12 May 2006 43.95 KB
Foundation of Liver Research 10 May 2006 31.01 KB
Haemophilia Society 12 May 2006 41.96 KB
Hepatitis C Trust 12 May 2006 31.92 KB
MRC Clinical Trials Unit 12 May 2006 22.24 KB
NHS Quality Improvement Scotland 10 May 2006 26.07 KB
Roche Products Limited 12 May 2006 43.94 KB
Royal College of General Practitioners 12 May 2006 58.06 KB
Royal College of Nursing 10 May 2006 14.22 KB
Royal College of Pathologists 12 May 2006 52.17 KB
Schering-Plough Ltd 10 May 2006 37.44 KB
Welsh Assembly Government 12 May 2006 42.28 KB
Welsh Assembly Government attachment 10 May 2006 13.73 KB

Expert comments on the ACD

Foster 10 May 2006 74.59 KB

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Appraisal consultation document

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Appraisal consultation document information

Final scope

Final scope 24 March 2005 34.78 KB

Evaluation Report

Evaluation Report
Hepatitis C - peginterferon alfa and ribavirin: assessment report 17 February 2006 1.21 MB
Overview 17 February 2006 75.26 KB
Consultee and commentator comments on the assessment report
Royal College of Pathologists (2) 17 February 2006 39.98 KB
Schering Plough Ltd 17 February 2006 41.56 KB
CPAP ACD - Consultee and commentator comments: Royal College of Nursing 17 February 2006 11.85 KB
Roche Products Ltd 17 February 2006 25.39 KB
NHS Quality Improvement Scotland 17 February 2006 15.88 KB
MRC Clinical Trials Unit 17 February 2006 30.24 KB
Mainliners 17 February 2006 32.15 KB
Haemophilia Alliance and UK Haemophilia Centre 17 February 2006 13.46 KB
British Society of Gastroenterology 17 February 2006 36.17 KB
British Association for the Study of the Liver 17 February 2006 13.21 KB
Manufacturer submissions (executive summary only)
Schering-Plough Ltd (2) 17 February 2006 19.16 KB
Roche Products Ltd (2) 17 February 2006 41.82 KB
Non manufacturer submissions
Royal College of Pathologists 17 February 2006 39.98 KB
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: Appraisal consultation - Royal College of Physicians 17 February 2006 21.66 KB
Royal College of Nursing (2) 17 February 2006 12.9 KB
Hepatitis C Trust 17 February 2006 44.73 KB
Haemophilia Society 17 February 2006 41.47 KB
Expert written personal statements
Morris 17 February 2006 43.13 KB
Maulayah 17 February 2006 26.11 KB
Gore 17 February 2006 24.41 KB
Foster 17 February 2006 19.61 KB

Final Protocol

Final Protocol 24 March 2005 75.14 KB

Response to consultee and commentator comments on the draft scope

Response to consultee and commentator comments on the draft scope 16 January 2005 40.64 KB

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Response to consultee and commentator comments on the provisional matrix of consultees and commentators 16 January 2005 21.97 KB

Archive Draft scope

Archive Draft scope 13 January 2005 33.48 KB

Archive Provisional matrix of consultees and commentators

Archive Provisional matrix of consultees and commentators 13 January 2005 29.51 KB

Background information

TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive 20 December 2013 111.64 KB

TA106 Hepatitis C - peginterferon alfa and ribavirin: - Appendix A - provisional matrix of stakeholders 14 October 2013 100.31 KB

TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013 14 October 2013 534.1 KB

Review decision - March 2008: table of comments 13 August 2008 135.33 KB

Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments 23 August 2006 42.03 KB

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination 12 May 2006 105.07 KB

Response to consultee and commentator comments on the ACD

Response to consultee and commentator comments on the ACD 12 May 2006 89.68 KB

Consultee and commentator comments on the ACD

Consultee and commentator comments on the ACD

Association of Nurses in Substance Abuse 12 May 2006 26.33 KB

British Society of Gastroenterology 12 May 2006 18.98 KB

Department of Health Development Agency 12 May 2006 43.95 KB

Foundation of Liver Research 10 May 2006 31.01 KB

Haemophilia Society 12 May 2006 41.96 KB

Hepatitis C Trust 12 May 2006 31.92 KB

MRC Clinical Trials Unit 12 May 2006 22.24 KB

NHS Quality Improvement Scotland 10 May 2006 26.07 KB

Roche Products Limited 12 May 2006 43.94 KB

Royal College of General Practitioners 12 May 2006 58.06 KB

Royal College of Nursing 10 May 2006 14.22 KB

Royal College of Pathologists 12 May 2006 52.17 KB

Schering-Plough Ltd 10 May 2006 37.44 KB

Welsh Assembly Government 12 May 2006 42.28 KB

Welsh Assembly Government attachment 10 May 2006 13.73 KB

Expert comments on the ACD

Foster 10 May 2006 74.59 KB

Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Appraisal consultation document

Final scope

Final scope 24 March 2005 34.78 KB

Evaluation Report

Evaluation Report

Hepatitis C - peginterferon alfa and ribavirin: assessment report 17 February 2006 1.21 MB

Overview 17 February 2006 75.26 KB

Consultee and commentator comments on the assessment report

Royal College of Pathologists (2) 17 February 2006 39.98 KB

Schering Plough Ltd 17 February 2006 41.56 KB

CPAP ACD - Consultee and commentator comments: Royal College of Nursing 17 February 2006 11.85 KB

Roche Products Ltd 17 February 2006 25.39 KB

NHS Quality Improvement Scotland 17 February 2006 15.88 KB

MRC Clinical Trials Unit 17 February 2006 30.24 KB

Mainliners 17 February 2006 32.15 KB

Haemophilia Alliance and UK Haemophilia Centre 17 February 2006 13.46 KB

British Society of Gastroenterology 17 February 2006 36.17 KB

British Association for the Study of the Liver 17 February 2006 13.21 KB

Manufacturer submissions (executive summary only)

Schering-Plough Ltd (2) 17 February 2006 19.16 KB

Roche Products Ltd (2) 17 February 2006 41.82 KB

Non manufacturer submissions

Royal College of Pathologists 17 February 2006 39.98 KB

Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: Appraisal consultation - Royal College of Physicians 17 February 2006 21.66 KB

Royal College of Nursing (2) 17 February 2006 12.9 KB

Hepatitis C Trust 17 February 2006 44.73 KB

Haemophilia Society 17 February 2006 41.47 KB

Expert written personal statements

Morris 17 February 2006 43.13 KB

Maulayah 17 February 2006 26.11 KB

Gore 17 February 2006 24.41 KB

Foster 17 February 2006 19.61 KB

Final Protocol

Final Protocol 24 March 2005 75.14 KB

Response to consultee and commentator comments on the draft scope

Response to consultee and commentator comments on the draft scope 16 January 2005 40.64 KB

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Response to consultee and commentator comments on the provisional matrix of consultees and commentators 16 January 2005 21.97 KB

Archive Draft scope

Archive Draft scope 13 January 2005 33.48 KB

Archive Provisional matrix of consultees and commentators

Archive Provisional matrix of consultees and commentators 13 January 2005 29.51 KB